A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of JZP926 in Participants Aged 10 Years and Older for the Treatment of Juvenile Myoclonic Epilepsy
Status: Recruiting
Location: See all (20) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2/Phase 3
SUMMARY
This study is being conducted to evaluate the safety and efficacy of JZP926 capsule in participants with Juvenile Myoclonic Epilepsy (JME).
Eligibility
Participation Requirements
Sex: All
Minimum Age: 10
Healthy Volunteers: f
View:
⁃ Participants are eligible to be included in the study only if all of the following criteria apply:
• Is ≥ 10 years of age at the time of screening.
• Has a diagnosis of JME per ILAE criteria as specified in the protocol.
• Has at least 4 myoclonic seizure days per 28 days historical seizure frequency.
Locations
United States
Arizona
Banner University Medical Center
NOT_YET_RECRUITING
Phoenix
California
Sutter Health
NOT_YET_RECRUITING
Sacramento
Connecticut
Yale University
NOT_YET_RECRUITING
New Haven
Florida
Pediatric Epilepsy & Neurology Specialists
NOT_YET_RECRUITING
Tampa
Georgia
Emory Healthcare
NOT_YET_RECRUITING
Atlanta
Savannah Neurology Specialists
RECRUITING
Savannah
Hawaii
Hawaii Pacific Neuroscience, LLC
RECRUITING
Honolulu
Idaho
Consultants in Epilepsy and Neurology
NOT_YET_RECRUITING
Boise
Illinois
Northwesthern Medicine
NOT_YET_RECRUITING
Chicago
Michigan
Corewell Health
NOT_YET_RECRUITING
Grand Rapids
New Jersey
Saint Peter's University Hospital
NOT_YET_RECRUITING
New Brunswick
New York
Boston Children's Health Physicians
NOT_YET_RECRUITING
Hawthorne
Northwell Health - Division of Pediatric Neurology
NOT_YET_RECRUITING
Lake Success
Weill Cornell Medicine - Pediatric Neurology
NOT_YET_RECRUITING
New York
Ohio
Cincinnati Children's Hospital
NOT_YET_RECRUITING
Cincinnati
Oregon
Oregon Health & Science University
NOT_YET_RECRUITING
Portland
Texas
Scottish Rite Hospital
NOT_YET_RECRUITING
Dallas
Virginia
Carilion Clinic Neurology
NOT_YET_RECRUITING
Roanoke
Sentara Neurology Specialists
NOT_YET_RECRUITING
Virginia Beach
Winchester Neurological Consultants
RECRUITING
Winchester
Contact Information
Primary
Clinical Trial Disclosure & Transparency
ClinicalTrialDisclosure@JazzPharma.com
215-832-3750
Time Frame
Start Date: 2026-09-18
Estimated Completion Date: 2028-08-01
Participants
Target number of participants: 260
Treatments
Experimental: JZP926 Capsule
Participants with JME will be randomized to JZP926 capsule based on weight-tiered dosing for a 16-week treatment period.
Placebo_comparator: Placebo
Participants with JME will be randomized to matching placebo based on weight-tiered dosing for a 16-week treatment period.
Experimental: Open-Label Extension: JZP926 Capsule
Participants completing Part A or Part B will have the option to continue into an open-label extension for up to 52 weeks, inclusive of a 4 week blinded transition.
Related Therapeutic Areas
Sponsors
Leads: Jazz Pharmaceuticals